Effect of Ifetroban, a Thromboxane a₂ Receptor Antagonist, in Stroke-Prone Spontaneously Hypertensive Rats

References

• Nagaoka A, Iwatsuka H, Suzuoki Z, Okamoto K. Genetic predisposition to stroke in spontaneously hypertensive rats. Am J Physiol. 1976; 230: 1354–1359
   PubMed Web of Science ®Google Scholar
• Yamori Y, Horie R, Handa H, Sato M, Fukase M. Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 1976; 7: 46–53
   PubMed Web of Science ®Google Scholar
• Mayhan W G. Role of prostaglandin H2-thromboxane A2 in responses of cerebral arterioles during chronic hypertension. Am J Physiol. 1992; 262: H539–H543
   Google Scholar
• Grover G J, Schumacher W A, Simon M, Parham C. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion. J Cardiovasc Pharmacol. 1988; 12: 701–709
   PubMed Web of Science ®Google Scholar
• Stier C T, Jr, Benter I F, Levine S. Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats. Stroke 1988; 19: 1145–1150
   PubMed Web of Science ®Google Scholar
• Nagaoka A, Kakihana M, Iwatsuka H. Effects of prostaglandin inhibitors on the onset of proteinuria and stroke in stroke-prone spontaneously hypertensive rats. Japan J Pharmacol. 1981; 31: 125–127
   PubMedGoogle Scholar
• Gryglewski R J, Nowak S, Kostka-Trabka E, Kusmiderski J, Dembinska-Kiec A, Bieron K, Basista M, Blaszczyk B. Treatment of ischaemic stroke with prostacyclin. Stroke 1983; 14: 197–202
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, DeSalvo A, Satta M A, Peskar B A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980; 17: 317–327
   PubMed Web of Science ®Google Scholar
• Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400–1403
   PubMed Web of Science ®Google Scholar
• The SALT Collaborative Group: Swedish aspirin low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–349
   PubMed Web of Science ®Google Scholar
• Gent M. Single studies and overview analyses: is aspirin of value in cerebral ischemia?. Stroke 1987; 18: 541–544
   PubMed Web of Science ®Google Scholar
• Misra R N, Brown B R, Sher P M, Patel M M, Hall S E, Han W C, Barrish J C, Floyd D M, Sprague P W, Morrison R A, Ridgewell R E, White R E, DiDonato G C, Harris D N, Hedberg A, Schumacher W, Webb M L, Ogletree M L. Thromboxane receptor antagonist BMS-180,291: A new pre-clinical lead. Bioorg Med Chem Letters 1992; 2: 73–76
   Web of Science ®Google Scholar
• Schumacher W A, Steinbacher T E, Youssef S, Ogletree M L. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins. 1992; 44: 389–397
   PubMedGoogle Scholar
• Ogletree M L, Harris D N, Schumacher W A, Webb M L, Misra R N. Pharmacological profile of BMS 180,291: A potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther. 1993; 264: 570–578
   PubMed Web of Science ®Google Scholar
• Misra R N, White R E, Ogletree M L. Ifetroban sodium. Drugs of the future 1994; 19: 107–110
   Google Scholar
• Grover G J, Schumacher W A, Ogletree M L. The thromboxane A2 receptor antagonist BMS-180291 reduces the severity of pacing-induced ischemia in dogs. J Cardiovasc Pharmacol. 1994; 24: 493–499
   PubMed Web of Science ®Google Scholar
• Gomoll A W, Grover G J, Ogletree M L. Myocardial salvage efficacy of the thromboxane receptor antagonist, BMS-180291, in the ferret and dog. J Cardiovasc Pharmacol. 1994; 24: 960–968
   PubMed Web of Science ®Google Scholar
• Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res. 1974; 34 and 35(Suppl I)I-143–I-153
   Google Scholar
• Brockway B P, Mills P A, Azar S H. A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radio-telemetry. Clin Exp Hypertens. 1991; A13: 885–895
   Google Scholar
• Bazil M K, Krulan C, Webb R L. Telemetric monitoring of cardiovascular paramenters in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993; 22: 897–905
   PubMed Web of Science ®Google Scholar
• Stier C T, Jr, Benter I F, Ahmad S, Zuo H, Selig N, Roethel S, Levine S, Itskovitz H D. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989; 13: 115–121
   PubMed Web of Science ®Google Scholar
• Yamori Y, Horie R, Tanase H, Fujiwara K, Nara Y, Lovenberg W. Possible role of nutritional factors in the incidence of cerebral lesions in stroke-prone spontaneously hypertensive rats. Hypertension 1984; 6: 49–53
   PubMed Web of Science ®Google Scholar
• Mistry M, Nasjletti A. Role of pressor prostanoids in rats with angiotensin-II salt-induced hypertension. Hypertension 1988; 11: 758–762
   PubMed Web of Science ®Google Scholar
• Testfamariam B, Ogletree M. Dissociation of endothelial cell dysfunction and blood pressure of SHR. Am J Physiol. 1995; 269: H189–H194
   Google Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Lee E T. Nonparametric methods for comparing survival distributions. Statistical Methods for Survival Data Analysis. Wadsworth Inc., Belmont 1980; 122–129
   Google Scholar
• Lin L, Mistry M, Stier C T, Jr, Nasjletti A. Role of prostanoids in renindependent and renin-independent hypertension. Hypertension 1991; 17: 517–525
   PubMed Web of Science ®Google Scholar
• Kudo K, Abe K, Chiba S, Sato M, Yasujima M, Kohzuki M, Omata K, Tanno M, Tsunoda K, Yoshinaga K. Role of thromboxane A2 in the hypotensive effect of captopril in essential hypertension. Hypertension 1988; 11: 147–152
   PubMed Web of Science ®Google Scholar
• Ritter JM, Barrow S E, Doktor H S, Stratton P D, Edwards J S, Henry J A, Gould S. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension 1993; 22: 197–203
   PubMed Web of Science ®Google Scholar